Fig. 2: ML-007 is more potent in reversing PCP-induced hyperlocomotion than xanomeline. | Neuropsychopharmacology

Fig. 2: ML-007 is more potent in reversing PCP-induced hyperlocomotion than xanomeline.

From: Preclinical efficacy of the muscarinic agonist ML-007 in psychosis models depends on both M1 and M4 receptors

Fig. 2

A Dose-dependent effects of ML-007 on reversal of PCP-induced hyperlocomotion in mice. ML-007 (0.3, 0.6, and 1 mg/kg IP) or vehicle was administered with PCP (5 mg/kg IP) as two separate administrations in rapid succession and monitored for locomotion for 30 min (n = 14-16/group, p < 0.0001). B Dose-dependent effects of xanomeline on reversal of PCP-induced hyperlocomotion in mice. Xanomeline (3, 6, and 10 mg/kg IP) or vehicle was administered with PCP (5 mg/kg IP) as two separate administrations in rapid succession and monitored for locomotion for 30 min (n = 14-16/group, p < 0.0001). Data are presented as cumulative distance over 5–15 min (*** indicates p < 0.0001 compared to vehicle-treated group, one-way ANOVA followed by Dunnett’s test, mean ± SEM).

Back to article page